Clinical Applications of Artificial Neural Networks in Pharmacokinetic Modeling

Abstract Artificial neural networks (ANNs) were designed to simulate the biological nervous system, where information is sent via input signals to a processor, resulting in output signals. ANNs are composed of multiple processing units that work together to learn, recognize patterns, and predict data. ANNs do not require regimented experimental design and have the ability to function even with incomplete data. They can be used in multifaceted, nonlinear systems with applications in the field of pharmacokinetic modeling. Pharmacokinetic/pharmacodynamic studies are used to predict meaningful correlations among doses administered, drug concentration levels, and pharmacological response. ANNs can be useful tools in analyzing the data involved in physiological processes, which can have vast amounts of complex variables with nonlinear relationships. ANNs are also convenient for handling data involving dosage form technology because they can simultaneously handle multiple independent and dependent variables without initial definition of causal relationships between the variables and response. The clinical applications of using ANNs in pharmacokinetic modeling are further discussed in this chapter, with specific examples from clinical studies being conducted.

[1]  S. Agatonovic-Kustrin,et al.  Application of artificial neural networks in HPLC method development. , 1998, Journal of pharmaceutical and biomedical analysis.

[2]  Abbas Sheikhtaheri,et al.  Developing and Using Expert Systems and Neural Networks in Medicine: A Review on Benefits and Challenges , 2014, Journal of Medical Systems.

[3]  S. Hu,et al.  Artificial neural networks aided deconvolving overlapped peaks in chromatograms. , 1996, Journal of chromatography. A.

[4]  Davide Verotta,et al.  Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  S. Agatonovic-Kustrin,et al.  ANN modeling of the penetration across a polydimethylsiloxane membrane from theoretically derived molecular descriptors. , 2001, Journal of pharmaceutical and biomedical analysis.

[6]  J Bourquin,et al.  Application of artificial neural networks (ANN) in the development of solid dosage forms. , 1997, Pharmaceutical development and technology.

[7]  Eric A. Wan,et al.  Finite impulse response neural networks with applications in time series prediction , 1994 .

[8]  Arjpolson Pukrittayakamee,et al.  Practical Training Framework for Fitting a Function and Its Derivatives , 2011, IEEE Transactions on Neural Networks.

[9]  Young-Sang Choi,et al.  Quantitative Structure-Activity Relationships (QSAR) Study of Flavonoid Derivatives for Inhibition of Cytochrome P450 1A2 , 2000 .

[10]  Johann Gasteiger,et al.  Neural networks and genetic algorithms in drug design , 2001 .

[11]  Ajaz S. Hussain,et al.  Modeling the Pharmacokinetics and Pharmacodynamics of a Unique Oral Hypoglycemic Agent Using Neural Networks , 2004, Pharmaceutical Research.

[12]  D. Maddalena,et al.  Applications of soft computing in drug design , 1998 .

[13]  David W. A. Bourne,et al.  Mathematical Modeling of Pharmacokinetic Data , 1995 .

[14]  Antonio J. Serrano,et al.  Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks , 2003, IEEE Transactions on Biomedical Engineering.

[15]  Leon Shargel,et al.  Applied biopharmaceutics and pharmacokinetics , 1980 .

[16]  D. Butina,et al.  Predicting ADME properties in silico: methods and models. , 2002, Drug discovery today.

[17]  Mohammad I. Saleh,et al.  Dosage Individualization of Warfarin Using Artificial Neural Networks , 2014, Molecular Diagnosis & Therapy.

[18]  Peter Veng-Pedersen,et al.  Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end? , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  J. Topliss,et al.  Chance factors in studies of quantitative structure-activity relationships. , 1979, Journal of medicinal chemistry.

[20]  Jie Chen,et al.  Use of artificial neural network to predict warfarin individualized dosage regime in Chinese patients receiving low-intensity anticoagulation after heart valve replacement. , 2014, International journal of cardiology.

[21]  Marek Wesolowski,et al.  Artificial neural networks: theoretical background and pharmaceutical applications: a review. , 2012, Journal of AOAC International.

[22]  L P Balant,et al.  Modelling during drug development. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  Hsinchun Chen,et al.  Estimating drug/plasma concentration levels by applying neural networks to pharmacokinetic data sets , 2000, Decis. Support Syst..

[24]  H. Metting,et al.  Neural networks in high-performance liquid chromatography optimization: response surface modeling. , 1996, Journal of chromatography. A.

[25]  S. Agatonovic-Kustrin,et al.  Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. , 2000, Journal of pharmaceutical and biomedical analysis.

[26]  D J Roe,et al.  Application of neural networks to population pharmacokinetic data analysis. , 1997, Journal of pharmaceutical sciences.

[27]  Antonio J. Serrano,et al.  Some Examples for Solving Clinical Problems Using Neural Networks , 2001, IWANN.

[28]  P. Veng‐Pedersen,et al.  Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. , 1994, Journal of pharmaceutical sciences.

[29]  Brian D. Ripley,et al.  Pattern Recognition and Neural Networks , 1996 .

[30]  Y. Pathak,et al.  Artificial Neural Network in Drug Delivery and Pharmaceutical Research , 2013 .

[31]  E Holmes,et al.  Quantitative structure-metabolism relationships (QSMR) using computational chemistry: pattern recognition analysis and statistical prediction of phase II conjugation reactions of substituted benzoic acids in the rat. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  M. Burnier,et al.  Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness? , 2006, BMC nephrology.

[33]  Jasper Dingemanse,et al.  Integrated Pharmacokinetics and Pharmacodynamics in Drug Development , 2007, Clinical pharmacokinetics.

[34]  Jonas S Almeida,et al.  Predictive non-linear modeling of complex data by artificial neural networks. , 2002, Current opinion in biotechnology.

[35]  K J Schaper,et al.  Quantitative structure-pharmacokinetic relationships and drug design. , 1981, Pharmacology & therapeutics.

[36]  Application of neural networks for the prediction of human pharmacokinetic parameters. , 1995, Methods and findings in experimental and clinical pharmacology.

[37]  H Ichikawa,et al.  Neural networks applied to quantitative structure-activity relationship analysis. , 1990, Journal of medicinal chemistry.

[38]  L. Snyder,et al.  Computer simulation for the prediction of separation as a function of pH for reversed-phase high-performance liquid chromatography. I. Accuracy of a theory-based model. , 1992, Journal of chromatography.

[39]  T Nagai,et al.  Formula optimization based on artificial neural networks in transdermal drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[40]  J. Taskinen,et al.  Neural network modeling for estimation of the aqueous solubility of structurally related drugs. , 1997, Journal of pharmaceutical sciences.

[41]  G. Camps,et al.  Artificial neural networks for the classification of potentially intoxicated patients treated with digoxin , 2000, Proceedings of the 22nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (Cat. No.00CH37143).

[42]  James L. McClelland Explorations In Parallel Distributed Processing , 1988 .

[43]  J A Dowell,et al.  Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. , 1999, Journal of pharmaceutical sciences.

[44]  S. K. Singh,et al.  QUANTITATIVE STRUCTURE PHARMACOKINETIC RELATIONSHIP USING ARTIFICIAL NEURAL NETWORK: A REVIEW , 2009 .

[45]  F. Huang,et al.  Assessment of chromatographic peak purity by means of artificial neural networks. , 1996, Journal of chromatography. A.

[46]  Neil Davey,et al.  The application and limitations of mathematical modelling in the prediction of permeability across mammalian skin and polydimethylsiloxane membranes , 2011, The Journal of pharmacy and pharmacology.

[47]  Shigeo Yamamura,et al.  Clinical application of artificial neural network (ANN) modeling to predict pharmacokinetic parameters of severely ill patients. , 2003, Advanced drug delivery reviews.

[48]  T. Rades,et al.  Use of artificial neural networks to predict quaternery phase systems from limited experimental data. , 1999, Journal of pharmaceutical and biomedical analysis.

[49]  M Tusar,et al.  Viscosity prediction of lipophilic semisolid emulsion systems by neural network modelling. , 2000, International journal of pharmaceutics.

[50]  A Bucinski,et al.  Pharmacological classification of drugs based on neural network processing of molecular modeling data. , 2000, Combinatorial chemistry & high throughput screening.

[51]  K. Behbehani,et al.  An artificial neural network-based controller for the control of induced paralysis using vecuronium bromide , 1997, Annals of Biomedical Engineering.

[52]  J V Gobburu,et al.  Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. , 1996, Journal of pharmaceutical sciences.

[53]  T Lavé,et al.  Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.